1. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC);Cheng;Proc Am Soc Clin Oncol,2011
2. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study;Santoro;Lancet Oncol,2012
3. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT);Cohn;Proc Am Soc Clin Oncol,2012
4. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma;Llovet;Clin Cancer Res,2012
5. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial;Bruix;J Hepatol,2012